tirzepatide/zepbound FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Lilly releases Zepbound® (tirzepatide) single-dose

Jonathan Kaplan, a board-certified plastic surgeon from San Francisco, has amassed 1.6 million views on TikTok (@realdrbae) with his warning: "Once you stop Ozempic, you will regain the weight." Kaplan highlights that patients often cease using Ozempic, initially prescribed for blood sugar management, after reaching their weight goalsonly to regain weight even when maintaining a diet and exercise routine

However, it varies from person to person and depending on the skin type

Studies and adverse event reports have raised concerns about a potential association between GLP-1 agonists and NAION, a serious eye condition involving reduced blood flow to the optic nerve

doi: 10.1186/s12937-023-00844-x

If Wegovy or another semaglutide product isn't delivering the results you expected, you're not aloneand the reason may be rooted in your unique genetic makeup and metabolic pathways

One is sumatriptan (50mg and 100mg)